aggressive in extend our Novocure, mission some morning. to you, Thank good cancer. Ingrid, of most the of and survival forms At is
for of lung Fields an therapy but recent for approval on important is non-small launching large we achievement in indication. have with are Treating efforts Optune focused largely cell non-small cancer Tumor next our glioblastoma lung Novocure. cell Launching Our cancer, the Lua
patients are in and eager to option needed urgently need. new We a therapeutic to bring
discussion and pipeline approved third a financial together for either approval followed Optune of PMA metastatic lung to post-platinum will of an clinical cancer our plans inhibitor lung non-small begin or FDA a and performance. ago, This update docetaxel. cancer, with cell Novocure's launch review non-small with treat the our review, morning, we by business immune weeks cell checkpoint X Lua quarter GBM
As know, glioblastoma thoracic to is and forms mesothelioma, cancer. brain therapy you TTFields already treat approved of and rare
Our in urgent with large lung to a population cancer therapy our line. be patient and need cell treat non-small the means and second innovative an will option an growing therapies effective unmet approval for for
been hired The for have preparing and team training. launch. we this lung summer was has months, extensive For over undergone the scientific
had at around have a substantial ELCC, ESMO, TTFields the ASCO, an therapy. opportunity about world, WCLC congresses for oncology physicians We and learn to presence including providing
fully needs. ensure understand boards we had We to physician advisory patient and have numerous the
team is a Our of caregivers. prepared and marketing resources providers, suite for with patients care teams,
Physician launched the approval, patient-focused Monday. in were the and the sales following websites team and was and trained our fully field day after
after completed physicians that approval. and lung received we pleased first to our shortly first are report our have prescription of We round certification,
is launch Our well underway.
of preparing in also are regulatory Japan We in for and Germany anticipation launch approvals.
As the lengthened time quarter, process review lines Europe. in MDR noted has last regulatory new
in than final hopeful taken months. a While longer the the for originally has we review projected, process decision remain coming
our are conversations In PMDA and Japan, ongoing. submitted productive the we to have application
proud team both cell our lung efforts of these be of am of to markets. to will We launch-ready in incredibly cancer bring non-small TTFields therapy the important patients. I upon approval
the our and Thank taken that this and our we the to across people physicians, have in have caregivers professionals families patients, and health many able trials. researchers celebrate Novocure Also, milestone. would contributed to and clinical been partnership not without of this part moment have So today you commitment care all. their
patients. for an is important achievement This
announced Danziger. a Novocure, will for Asaf success. planned at of position our We month, prepare Novacure for this changes team CEO, we end year at executive long-term retirement new we Last that to are to As the pleased our implement the chapter of
strong with our XX regulatory we shepherded company our years a to been employees. Asaf successful leaders. Under when retire. venture international the prepare, company has cultivating and in small X,XXX to Asaf clinical GBM we launch team trials, for would our Novocure knew Israel has through advances have the over to And choose from come of successful an business. and would approvals, We Asaf been grown have day of leadership, a engineering of
was expanding process global began to goal identify find commercial a opportunities. our organization and clinical to successor, knowledge with the experience our of candidate institutional deep and When a the substantial Asaf Board and managing understanding
Ashley all these Cordova embodies characteristics. of
been global the and scaling strategic has record as joining operations commitment patients integral to infrastructure is Ashley XXXX. in Her as our to Novocure's vision CFO. accomplishment exceptional her company since and are of our
confident stage to is next right she Novocure's Ashley choice growth. are accepted and challenge of We the drive has delighted the
of week will Brackmann, also most our brings This morning, replacing X. joins was we of the Christoph to the who's is Senior important Moderna's pandemic. the up recently be team. COVID role. to Vice Ashley Christoph Finance perspective Novocure Novocure as assume executive during an at external addition will biotechnology in position and Christoph Christophe and he instrumental next a CFO our pharmaceutical the and this this was joined wealth President in experience Moderna, January CFO, scale announced on industries.
of [ over retirement our Finally, as in the Pravas took Macon following October, COO, Wilco Greenhouse. ]
additions these to will executive the levels and next our have the growth. place of we Novocure that leadership, to in the With I Board believe lead team
thanks over Asaf years dedication to personal would pass like of my I to call Novocure. I for Ashley, to extend XX his to the Before
when succeeded know young we exist to were without Tumor Asaf today bring Asaf. and journey I therapy to not Fields men not embarked Novocure on I we patients, would have and would and the Treating
Ashley?
